| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.27 | 8e-14 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.35 | 3e-09 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.25 | 8e-08 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 9e-08 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-07 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.31 | 3e-07 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.29 | 3e-07 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-06 |